Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2022; 28(26): 3243-3257
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3243
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3243
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
Francesco Bellanti, Aurelio Lo Buglio, Gaetano Serviddio, Gianluigi Vendemiale, Department of Medical and Surgical Sciences, University of Foggia, Foggia 71122, Italy
Michał Dobrakowski, Aleksandra Kasperczyk, Sławomir Kasperczyk, Department of Biochemistry, Medical University of Silesia in Katowice, Zabrze 41-808, Poland
Palok Aich, School of Biological Sciences, National Institute of Science Education and Research, Khurdha 752050, India
Shivaram P Singh, Department of Gastroenterology, SCB Medical College, Cuttack 753007, India
Author contributions: Bellanti F and Vendemiale G designed and coordinated the study; Bellanti, F, Lo Buglio A, Dobrakowsky M, and Kasperczyk A performed the experiments, acquired and analyzed data; Bellanti F, Lo Buglio A, Dobrakowsky M, Kasperczyk A, Kasperczyk S, Serviddio G, Singh SP, Aich P, and Vendemiale G interpreted the data; Bellanti F wrote the manuscript; Kasperczyk S, Serviddio G, Singh SP, Aich P, and Vendemiale G supervised the manuscript; and all authors approved the final version of the article.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at the University of Foggia.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The Authors have read the STROBE statement - checklist of items, and the manuscript was prepared and revised according to the STROBE statement - checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Francesco Bellanti, MD, PhD, Associate Professor, Department of Medical and Surgical Sciences, University of Foggia, viale Pinto, 1, Foggia 71122, Italy. francesco.bellanti@unifg.it
Received: January 10, 2022
Peer-review started: January 10, 2022
First decision: March 8, 2022
Revised: March 18, 2022
Accepted: June 18, 2022
Article in press: June 18, 2022
Published online: July 14, 2022
Peer-review started: January 10, 2022
First decision: March 8, 2022
Revised: March 18, 2022
Accepted: June 18, 2022
Article in press: June 18, 2022
Published online: July 14, 2022
Core Tip
Core Tip: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder, and it is often associated with type 2 diabetes mellitus (T2DM). Diabetic patients often suffer from advanced NAFLD and are keen on progressing toward severe fibrosis and end-stage liver disease. There is no approved treatment for NAFLD, but new drug classes introduced to treat T2DM can exert favorable effects beyond glucose control. This pilot study demonstrates that treatment with sodium glucose cotransporter-2 inhibitors in patients with T2DM and NAFLD is associated with improving liver steatosis and fibrosis markers and circulating pro-inflammatory and redox status.